SCYNEXIS to Provide a Corporate Update and Report Third Quarter 2021 Financial Results on November 10

Rhea-AI Impact

(Neutral)

Rhea-AI Sentiment

(Neutral)

Tags

earnings

11/03/2021 - 08:30 AM

JERSEY CITY, N.J., Nov. 03, 2021 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced it will host a conference call and live webcast at 8:30 a.m. ET on Wednesday, November 10, 2021, to provide a corporate update and discuss the Company’s financial results for the third quarter ended September 30, 2021.

Conference call and webcast details:

Investors (domestic): (877) 705-6003
Investors (international): (201) 493-6725
Conference ID: 13724235
Webcast: https://viavid.webcasts.com/starthere.jsp?ei=1504710&tp_key=3a6a6b5742

A live audio webcast can be accessed by visiting the Investor Relations section of the Company’s website, www.scynexis.com. A replay of the webcast will be archived on the SCYNEXIS website for 90 days following the event.

About SCYNEXIS

SCYNEXIS, Inc. (NASDAQ: SCYX) is a biotechnology company pioneering innovative medicines to help millions of patients worldwide overcome and prevent difficult-to-treat infections that are becoming increasingly drug-resistant. SCYNEXIS scientists are developing the company’s lead asset, ibrexafungerp (formerly known as SCY-078), as a broad-spectrum, systemic antifungal for multiple fungal indications in both the community and hospital settings. SCYNEXIS has initiated the launch of its first commercial product in the U.S., BREXAFEMME ^® (ibrexafungerp tablets), which was approved by the U.S. Food and Drug Administration (FDA) on June 1, 2021. In addition, late-stage clinical development of ibrexafungerp for the prevention of recurrent vulvovaginal candidiasis (rVVC) and the treatment of life-threatening invasive fungal infections in hospitalized patients is ongoing. For more information, visit www.scynexis.com.

CONTACT:

Investor Relations
Irina Koffler
LifeSci Advisors
Tel: (646) 970-4681
ikoffler@lifesciadvisors.com

Media Relations
Gloria Gasaatura
LifeSci Communications
Tel: (646) 970-4688
ggasaatura@lifescicomms.com

SCYNEXIS, Inc.

NASDAQ:SCYX

SCYX Rankings

#4574 Ranked by Market Cap

N/A Ranked by Dividends

SCYX Latest News

Apr 30, 2024

SCYNEXIS Presented Preclinical Data on Second Generation Fungerp SCY-247 at the Congress of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID Global, Formerly ECCMID)

Apr 9, 2024

SCYNEXIS to Present Preclinical Data on Second Generation Fungerp SCY-247 at the 34th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)

Mar 28, 2024

SCYNEXIS Reports Full Year 2023 Financial Results and Provides Corporate Update

Jan 30, 2024

SCYNEXIS to Participate in Guggenheim’s 6th Annual Biotechnology Conference

Jan 29, 2024

SCYNEXIS Presented Preclinical Data on Second Generation Fungerp SCY-247 against Mucormycosis at the 11th Advances Against Aspergillosis and Mucormycosis Conference

SCYX Stock Data

Market Cap 66.87M

Float 37.27M

Insiders Ownership 2.84%

Institutions Ownership 48.35%

Short Percent 2.59%

Industry Pharmaceutical Preparation Manufacturing

Sector Manufacturing

Website Link

Country United States of America

City JERSEY CITY

About SCYX

scynexis, inc. is a pharmaceutical company committed to the discovery, development and commercialization of novel anti-infectives to address significant unmet therapeutic needs. our scientists have extensive experience in the life sciences industry having, together and individually, been involved in the discovery and development of innovative medicines over a broad range of therapy areas. we are developing our lead product candidate, scy-078, a novel antifungal in phase 2, as a novel oral and intravenous drug for the treatment of serious and life-threatening invasive fungal infections in humans.

Trending News